Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dr Reddy’s Laboratories ( (RDY) ) has shared an update.
On June 3, 2025, Dr. Reddy’s Laboratories announced the allotment of 57,840 equity shares to eligible employees who exercised their stock options under the company’s Employee Stock Options Scheme, 2002. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially enhancing employee satisfaction and aligning their interests with those of the company. The issuance of these shares, which are fully paid up at a par value of Re.1 each, increases the total issued share capital to Rs. 83,45,14,205, reflecting the company’s robust growth and commitment to employee engagement.
The most recent analyst rating on (RDY) stock is a Buy with a $18.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. It operates in the healthcare industry, focusing on the development and manufacturing of generic medications, active pharmaceutical ingredients, and proprietary products. The company is listed on multiple stock exchanges, including the BSE, NSE, and NYSE, and is known for its commitment to providing affordable and innovative medicines.
Average Trading Volume: 2,055,866
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.13B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.